KR870006900A - 항바이러스 조성물 - Google Patents

항바이러스 조성물 Download PDF

Info

Publication number
KR870006900A
KR870006900A KR870000667A KR870000667A KR870006900A KR 870006900 A KR870006900 A KR 870006900A KR 870000667 A KR870000667 A KR 870000667A KR 870000667 A KR870000667 A KR 870000667A KR 870006900 A KR870006900 A KR 870006900A
Authority
KR
South Korea
Prior art keywords
composition
antiviral compound
pharmacologically acceptable
virus infection
nucleoside transport
Prior art date
Application number
KR870000667A
Other languages
English (en)
Inventor
폴 지메르만 토마스
울베르그 제랄드
Original Assignee
원본미기재
더 웰컴 화운데이숀 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 더 웰컴 화운데이숀 리미티드 filed Critical 원본미기재
Publication of KR870006900A publication Critical patent/KR870006900A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음.

Description

항바이러스 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. (a) 바이러스가 유도한 적어도 하나의 효소에 의해 생체내에서 바이러스성중 DNA합효소의 기질 또는 억제제로 전환되는 항바이러스 화합물과, (b) 비독성인 뉴클레오시드 운반 억제제로 구성되며, 이 (a)(b)와 성분은 상승적 항바이러스 효과가 얻어지는 비로 사용되는 것을 특징으로 하는 항 바이러스 조성물.
  2. 제1항에 있어서, 항 바이러스 화합물은 하기식(I)의 화합물과 이것의 약리적 허용 염 및 에스테르인 것을 특징으로 하는 조성물.
    상기식에서, X는 산소 또는 황, R은 수소, 히드록시 또는 아미노 및 Y는 수소 또는 히드록시메틸이다.
  3. 제1항 또는 제2항에 있어서, 항바이러스 호합물은 9-[(2-히드록시에톡시)메틸] 구아닌 및 이것의 약리학적 허용염 및 에스테르인 것을 특징으로 하는 조성물.
  4. 제1항 또는 제2항에 있어서, 항바이러스 화합물은 2-아미노-9-[(2-히드록시에톡시)메틸]퓨린인 것을 특징으로 하는 조성물.
  5. 제1항 내지 제4항중 어느 한 항에 있어서, 뉴클레오시드 운반 억제제는 딜아젭, 디피리다몰 또는 6-[(4-니트로벤질)티올]-9-(B-D-리보푸라노실)퓨린 또는 이것의 약리학적 허용 염인 것을 특징으로 하는 조성물.
  6. 적어도 하나의 약학적 담체 또는 부형제와 제1항 내지 제5항중 어느 한 항의 조성물을 함유하는 약학적 제제.
  7. 제1항 내지 제6항 중 어느 한항에 있어서 의학적 치료에 사용되는 조성물.
  8. 제7항에 있어서 포진 바이러스 감염증을 치료 또는 예방하는데 사용되는 조성물.
  9. 제8항에 있어서, 포진 심플렉스 또는 수두대상포진 바이러스 감염증의 치료 또는 예방에 사용되는 조성물.
  10. 포진 바이러스 감염증의 치료 또는 예방을 위한 의약제 제조에 제1항 내지 제5항의 조성물을 사용하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR870000667A 1986-01-30 1987-01-28 항바이러스 조성물 KR870006900A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8602346 1986-01-30
GB868602346A GB8602346D0 (en) 1986-01-30 1986-01-30 Antiviral combinations

Publications (1)

Publication Number Publication Date
KR870006900A true KR870006900A (ko) 1987-08-13

Family

ID=10592262

Family Applications (1)

Application Number Title Priority Date Filing Date
KR870000667A KR870006900A (ko) 1986-01-30 1987-01-28 항바이러스 조성물

Country Status (20)

Country Link
US (1) US4897394A (ko)
EP (1) EP0235931B1 (ko)
JP (1) JPS62195337A (ko)
KR (1) KR870006900A (ko)
AT (1) ATE54414T1 (ko)
AU (1) AU590817B2 (ko)
CA (1) CA1283361C (ko)
DD (1) DD261095A5 (ko)
DE (1) DE3763597D1 (ko)
DK (1) DK46787A (ko)
ES (1) ES2031883T3 (ko)
FI (1) FI870377A (ko)
GB (1) GB8602346D0 (ko)
GR (1) GR3000638T3 (ko)
HU (1) HU198394B (ko)
IL (1) IL81422A0 (ko)
MC (1) MC1791A1 (ko)
PL (1) PL263871A1 (ko)
PT (1) PT84219B (ko)
ZA (1) ZA87667B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4782065A (en) * 1984-04-18 1988-11-01 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections
US4800081A (en) * 1984-04-18 1989-01-24 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections
US4849412A (en) * 1986-06-05 1989-07-18 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections
US5879700A (en) * 1991-10-15 1999-03-09 Hostetler; Karl Y. Nucleoside analogue phosphates for topical use
US5580571A (en) * 1991-10-15 1996-12-03 Hostetler; Karl Y. Nucleoside analogues
WO1994018979A2 (en) * 1993-02-19 1994-09-01 Southern Research Institute Methods of treatment of viral infections using carbocyclic deoxyguanosine analogs
WO1994023723A1 (en) * 1993-04-15 1994-10-27 New York University Adenosine receptor agonists for the promotion of wound healing
US6015573A (en) * 1993-05-12 2000-01-18 Hostetler; Karl Y. Nucleoside phosphate therapy for viral infection
WO1994026273A1 (en) * 1993-05-12 1994-11-24 Hostetler Karl Y Acyclovir derivatives for topical use
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
US6440980B1 (en) 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US5677308A (en) * 1996-12-19 1997-10-14 Lerner; A. Martin Method for alleviating spasmodic torticollis
US5872123A (en) * 1997-02-18 1999-02-16 Lerner; A. Martin Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
US6399622B1 (en) 1997-02-18 2002-06-04 A. Martin Lerner Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
US6537997B1 (en) 1997-02-18 2003-03-25 A. Martin Lerner Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
JP2005519868A (ja) * 2001-10-16 2005-07-07 アバニール・ファーマシューティカルズ ｎ−ドコサノールによるウイルス阻害
US20130172536A1 (en) * 2011-08-16 2013-07-04 Shenzhen Weiguang Biological Products Co.,Ltd. Intravenous Cytomegalovirus Human Immune Globulin and Manufacturing Method Thereof
US20140100238A1 (en) 2012-10-04 2014-04-10 Ohio State University Method of diagnosing and treating epstein barr virus-based myalgic encephalomyelitis chronic fatigue syndrome patients
CN105079404A (zh) * 2015-09-07 2015-11-25 夏云强 一种治疗多重耐药菌所致感染性创面的中药外洗剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2080106B (en) * 1980-07-18 1984-03-07 Weelcome Foundation Ltd Acyclovin preparations
KR890001487B1 (ko) * 1982-10-14 1989-05-04 더 웰컴 파운데이숀 리미티드 푸린 유도체의 제조방법
GB8320308D0 (en) * 1983-07-28 1983-09-01 Wellcome Found Antiviral combinations
PT82580B (pt) * 1985-05-15 1989-01-17 Wellcome Found Processo para a preparacao de 2',3'- didesoxinucleosidos e de composicoes farmaceuticas que os contem
DE3627024A1 (de) * 1985-09-24 1987-04-02 Hoechst Ag In 6- und 9-stellung substituierte 2-aminopurine, ihre verwendung, diese purine enthaltende arzneimittel und verfahren zur herstellung der purine
MY101126A (en) * 1985-12-13 1991-07-31 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
FI870377A0 (fi) 1987-01-29
DD261095A5 (de) 1988-10-19
DK46787D0 (da) 1987-01-29
ZA87667B (en) 1988-09-28
GR3000638T3 (en) 1991-09-27
JPS62195337A (ja) 1987-08-28
MC1791A1 (fr) 1987-10-22
EP0235931B1 (en) 1990-07-11
PT84219A (en) 1987-02-01
FI870377A (fi) 1987-07-31
IL81422A0 (en) 1987-08-31
DE3763597D1 (de) 1990-08-16
PT84219B (pt) 1989-07-31
PL263871A1 (en) 1988-05-12
HUT42941A (en) 1987-09-28
AU6813587A (en) 1987-08-06
EP0235931A1 (en) 1987-09-09
AU590817B2 (en) 1989-11-16
ES2031883T3 (es) 1993-01-01
GB8602346D0 (en) 1986-03-05
DK46787A (da) 1987-07-31
HU198394B (en) 1989-10-30
US4897394A (en) 1990-01-30
ATE54414T1 (de) 1990-07-15
CA1283361C (en) 1991-04-23

Similar Documents

Publication Publication Date Title
KR870006900A (ko) 항바이러스 조성물
CA2005815A1 (en) Antiviral acyclic nucleoside derivatives
MY121839A (en) Antiviral purine derivatives
DK1104436T3 (da) Beta-L-2'-deoxy-nukleosider til behandling af hepatitis B-virus
MY103760A (en) Therapeutic nucleosides
AR035711A1 (es) Prodrogas 3' de 2'-desoxi-beta-l-nucleosidos; sus composiciones farmaceuticas; metodo para el tratamiento o profilaxis de una infeccion del virus de la hepatitis b y sus usos para la manufactura de composiciones farmaceuticas
ES2108014T3 (es) Composicion antiviral de 3'-azido-2',3'-dideoxi-5-metilcitidina.
Baba et al. Synergistic antiviral effects of antiherpes compounds and human leukocyte interferon on varicella-zoster virus in vitro
KR890001560A (ko) 항바이어러스 조성물
KR960704464A (ko) 포유동물 세포에서의 뉴클레오사이드와 뉴클레오베이스 수송억제 방법 및 바이러스 복제억제 방법(method for inhibiting nucleoside and nucleoside transport and virus replication in mammalian cells)
ES2063147T3 (es) Compuestos antivirales.
KR950703976A (ko) 아시클로비르 유사 화합물과 2′-비닐 치환 뉴클레오시드 유사체를 함유하는 바이러스 감염 치료용 조성물(Compositions Containing Acyclovir-Like Compounds and 2′-Vinyl substituted Nucleoside Analogs for the Treatment of Viral Infections)
CY1117836T1 (el) Βητα-l-2'-δεοξυ-νουκλεοσιδια για την θεραπεια ηπατιτιδας β
GEP19970908B (en) Esters of 9-(2-hydroxyethoxymethyl)guanine having antiviral properties
MX9709782A (es) Derivados de aciclovir para aplicacion topica.
RU98100411A (ru) Производные ацикловира для локального применения

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid